All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy


Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
You're logged in! Click here any time to manage your account or log out.
You're logged in! Click here any time to manage your account or log out.

Impact of delayed venetoclax-based treatment on overall survival in newly diagnosed AML

Jun 25, 2024
Learning objective: After reading this article, learners will be able to cite a new clinical development in acute myeloid leukemia.

Baden et al. published an article in Haematologica, assessing the impact on overall survival of time from diagnosis to treatment initiation in patients with acute myeloid leukemia (AML) receiving venetoclax-based combination therapies. Real-world data from the Study Alliance Leukemia (SAL) registry (n = 138) and the global healthcare network TriNetX (n = 717) were analyzed retrospectively.

Key learnings

Median overall survival in patients receiving treatment within the first 9 days of diagnosis (early) vs those receiving treatment on or after Day 10 (later) was:

  • 7.7 vs 9.6 months, respectively, in the SAL registry (p = 0.42); and
  • 7.5 vs 7.2 months, respectively, in the TriNetX network (p = 0.41).

Overall survival after 12 months was similar between patients receiving early and later treatment, and this was maintained in patients aged ≥75 years and in those with leukocytes ≥20 × 109/L.

There were no significant differences in treatment safety, event-free survival, and relapse-free survival between patients receiving early vs later treatment.

The study suggests that a delay in venetoclax based treatment in newly diagnosed AML does not accumulate risk factors, affect treatment efficacy, or influence outcomes.

  • Further, delaying treatment could potentially improve outcomes in specific subsets of the AML population, such as those with targetable lesions and reversible comorbidities.

  1. Baden D, Zukunft S, Hernandez G, et al. Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens. Haematologica. 2024. Online ahead of print. DOI:10.3324/haematol.2024.285225


Subscribe to get the best content related to AML delivered to your inbox